Clinical Trial Update: Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura [EARLY_Phase 1]

View source ↗

Summary

Phase 1 study evaluating rituximab plus prednisone as first-line therapy for immune thrombocytopenia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• PREDNISONE (Prednisone)
• Rituxan (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Nonneoplastic Condition | EARLY_Phase 1 | Status: COMPLETED